Blockchain Registration Transaction Record

MJNA and AXIM Partner on Water-Soluble Cannabinoid Patent for Enhanced Treatments

Medical Marijuana, Inc. and AXIM Biotechnologies form strategic alliance to research water-soluble cannabinoid patent, enhancing bioavailability for anxiety and seizure treatments.

This alliance matters because it addresses a critical barrier in cannabinoid therapy: poor water solubility that limits absorption and efficacy. By developing cannabinoids that are over 300 times more water-soluble, this technology could revolutionize treatment delivery, making cannabinoid-based medicines more effective and accessible for conditions like anxiety and seizures. Improved bioavailability means patients might require lower doses, reducing potential side effects and costs. As the cannabis and hemp-derived CBD markets grow, innovations like this could accelerate FDA approvals and mainstream adoption, impacting millions seeking alternative treatments. For investors, it signals MJNA's strategic move to strengthen its IP portfolio and R&D capabilities, potentially driving future revenue through licensing and product development in a competitive industry.